Biblio Discovery — Demo Discovery Service

4 results for "Luke Slade"

Showing 1–4 · 0.15 seconds · RSS

  1. Journal Article

    Hydrogen sulfide supplementation as a potential treatment for primary mitochondrial diseases

    Luke Slade; Colleen S. Deane; Nathaniel J. Szewczyk et al.

    Pharmacological Research, Vol. 203 · 2024 · English · DOAJ Scopus

    Primary mitochondrial diseases (PMD) are amongst the most common inborn errors of metabolism causing fatal outcomes within the first decade of life. With marked heterogeneity in both inheritance patterns and physiological manifestations, these conditions present distinct challenges for targeted…

  2. Journal Article

    An evaluation of the role of miR-361-5p in senescence and systemic ageing

    Emad Manni; Nicola Jeffery; David Chambers et al.

    Experimental Gerontology, Vol. 174 · 2023 · English · DOAJ Scopus

    Senescent cells are key regulators of ageing and age-associated disease. MicroRNAs (miRs) are a key component of the molecular machinery governing cellular senescence, with several known to regulate important genes associated with this process.We sought to identify miRs associated with both…

  3. Journal Article

    Sulfur amino acid supplementation displays therapeutic potential in a C. elegans model of Duchenne muscular dystrophy

    Rebecca A. Ellwood; Luke Slade; Jonathan Lewis et al.

    Communications Biology, Vol. 5 No. 1 · 2022 · English · DOAJ Scopus

    A C. elegans model of Duchenne muscular dystrophy reveals a potential role for disrupted sulfur metabolism in the disease and thus the therapeutic potential of sulfur amino acid supplementation.

  4. Journal Article

    Bisphosphonates attenuate age‐related muscle decline in Caenorhabditis elegans

    Luke Slade; Shelby E. Bollen; Joseph J. Bass et al.

    Journal of Cachexia, Sarcopenia and Muscle, Vol. 14 No. 6 · 2023 · English · DOAJ Scopus

    Abstract Background Age‐related muscle decline (sarcopenia) associates with numerous health risk factors and poor quality of life. Drugs that counter sarcopenia without harmful side effects are lacking, and repurposing existing pharmaceuticals could expedite realistic clinical options. Recent…